Zyvox® (linezolid), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections

被引：0
作者：
Brickner, Steven J. [1 ]
Barbachyn, Michael R. [2 ]
Hutchinson, Douglas K. [3 ]
Manninen, Peter R. [4 ]
机构：
[1] Pfizer Inc, Antibacterials Chem, Groton New London Labs, Groton, CT 06340 USA
[2] Pfizer Inc, Dept Chem, Ann Arbor, MI 48105 USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
[4] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 233卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
257-MEDI
引用
收藏
页码：607 / 607
页数：1
相关论文
共 50 条
[31]   New opportunities for the treatment of severe Gram-positive infections [J].
不详 .
PRESSE MEDICALE, 2003, 32 (13) :S3-S3
[32]   Diagnostic and Treatment Considerations for Prosthetic Joint Infections: Sonication and New Gram-Positive Agents [J].
Julie E. Reznicek ;
Angela Hewlett .
Current Treatment Options in Infectious Diseases, 2015, 7 (4) :335-341
[33]   Cost effectiveness analysis of linezolid vs. teicoplanin for the treatment of serious gram-positive bacterial infections in a multinational randomized trial [J].
Li, JZ ;
Willke, RJ ;
Balan, DA ;
Nathwani, D ;
López, H ;
Rittenhouse, BE ;
Tavacoli, M ;
Mozaffari, E .
VALUE IN HEALTH, 2003, 6 (03) :259-260
[34]   Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections [J].
Chien, JW ;
Kucia, ML ;
Salata, RA .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :146-151
[35]   Linezolid: Its role in the treatment of gram-positive, drug-resistant bacterial infections [J].
Ament, PW ;
Jamshed, N ;
Horne, JP .
AMERICAN FAMILY PHYSICIAN, 2002, 65 (04) :663-670
[36]   Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates [J].
Deville, JG ;
Adler, S ;
Azimi, PH ;
Jantausch, BA ;
Morfin, MR ;
Beltran, S ;
Edge-Padbury, B ;
Naberhuis-Stehouwer, S ;
Bruss, JB .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) :S158-S163
[37]   Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections [J].
Lopez-Garcia, Belen ;
Luque, Sonia ;
Roberts, Jason A. ;
Grau, Santiago .
JOURNAL OF INFECTION, 2015, 71 (05) :604-607
[38]   Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia [J].
Rubinstein, Ethan ;
Corey, G. Ralph ;
Stryjewski, Martin E. ;
Kanafani, Zeina A. .
EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (17) :2737-2750
[39]   Telavancin: An antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections [J].
Leonard, Steven N. ;
Rybak, Michael J. .
PHARMACOTHERAPY, 2008, 28 (04) :458-468
[40]   Quinupristin/dalfopristin - a novel approach for the treatment of serious Gram-positive infections - Preface [J].
Wood, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :III-III
12345